XTL BIOPHARMACEUTICALS LTD.

Ajouter à une liste

Communiqués XTL Biopharmaceuticals Ltd. Nasdaq

Actions

XTLB

US98386D4060

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:30:00 04/09/2026			Varia. 5j.	Varia. 1 janv.
2,530 ^USD	+1,20%		+2,43%	+9,05%

30/06	XTL Biopharmaceuticals Ltd. publie ses résultats pour l'exercice clos le 31 décembre 2025	CI
30/06	XTL Biopharmaceuticals Ltd. (TASE:XTLB) a acquis Psyga Bio Ltd.	CI

Communiqués

30/06	XTL Completed the Acquisition of Psyga Bio Ltd.	AQ
22/05	XTL Announces Receipt of Staff Delist Determination from Nasdaq	AQ
29/04	XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies	AQ
03/02/25	XTL Biopharmaceuticals : Immediate Report	PU
20/11/24	XTL Biopharmaceuticals : Form 6 K As previously disclosed, on November 11, 2024 entered into a settlement agreement	PU
19/11/24	XTL Biopharmaceuticals : Purchase Agreement Form 6 K	PU
12/11/24	XTL Biopharmaceuticals : Purchase Agreement Form 6 K	PU
14/08/24	XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million	AQ
22/07/24	XTL Biopharmaceuticals : Immediate Report	PU
22/07/24	XTL Biopharmaceuticals : Report Of Foreign Private Issuer Form 6 K	PU
12/06/24	XTL Biopharmaceuticals : Immediate Report of Meeting	PU
12/06/24	XTL Biopharmaceuticals : NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 22, 2024 Form 6 K	PU
02/04/24	XTL Biopharmaceuticals : Report Of Foreign Private Issuer - Form 6-K	PU
21/03/24	XTL Biopharmaceuticals : Immediate Report of Meeting	PU
21/03/24	XTL Biopharmaceuticals : NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 30, 2024 - Form 6-K	PU
20/03/24	XTL To Aquire The Social Proxy	AQ
15/11/23	XTL Biopharmaceuticals : Report Of Foreign Private Issuer - Form 6-K	PU
20/10/23	XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency	AQ
25/08/21	XTL Biopharmaceuticals : OPERATING AND FINANCIAL REVIEW AND PROSPECTS (Form 6-K)	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse

Filtres

Les meilleurs outils réservés aux abonnés pour augmenter la performance de vos investissements !